Inhibikase Therapeutics (IKT) FDA Approvals $1.38 -0.07 (-4.83%) Closing price 04:00 PM EasternExtended Trading$1.38 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest Inhibikase Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Inhibikase Therapeutics (IKT). Over the past two years, Inhibikase Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as IKT-001. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. IKT-001 FDA Regulatory Timeline and Events IKT-001 is a drug developed by Inhibikase Therapeutics for the following indication: Pulmonary Arterial Hypertension. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Designation Grant - July 23,2026Designation Grant Orphan DrugDrug: IKT-001Announced Date: July 23, 2026Indication: Pulmonary Arterial HypertensionAnnouncementInhibikase Therapeutics, Inc announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of PAH.AI SummaryInhibikase Therapeutics announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to IKT-001, its lead drug candidate for pulmonary arterial hypertension, or PAH. IKT-001 is a prodrug of imatinib mesylate, meaning it is designed to turn into the active medicine in the body. The orphan designation is given to investigational treatments for rare diseases that affect fewer than 200,000 people in the United States. This designation is important because it recognizes PAH as a rare condition and highlights the potential need for new treatment options. For Inhibikase, the FDA decision may also support further development of IKT-001 as it continues testing the drug for this serious disease.Read AnnouncementEnrollment Update - April 7,2026Enrollment Update Phase 3Drug: IKT-001Announced Date: April 7, 2026Indication: Pulmonary Arterial HypertensionAnnouncementInhibikase Therapeutics, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 study IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332).AI SummaryInhibikase Therapeutics announced that the first patient has been enrolled in its pivotal Phase 3 study, IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332). The study tests IKT-001, the Company’s investigational therapy for pulmonary arterial hypertension (PAH), and this enrollment marks the start of the late-stage trial. The IMPROVE-PAH trial will measure pulmonary vascular resistance and other key outcome variables to evaluate whether IKT-001 improves hemodynamics and clinical results for people with PAH. As a pivotal Phase 3 study, its findings will be central to assessing the drug’s safety and effectiveness. The program will continue enrolling patients across trial sites, with subsequent data readouts and analyses planned as the study progresses.Read AnnouncementProvided Update - November 20,2025Provided Update Phase 3Drug: IKT-001Announced Date: November 20, 2025Indication: Pulmonary Arterial HypertensionAnnouncementInhibikase Therapeutics, Inc. announced that it expects to advance IKT-001 to a global pivotal Phase 3 clinical study in PAH.AI SummaryInhibikase announced it expects to advance IKT-001, a prodrug of imatinib, into a global pivotal Phase 3 study called IMPROVE-PAH, planned to start in the first quarter of 2026. IKT-001 is designed to deliver imatinib’s anti-proliferative benefits in pulmonary arterial hypertension (PAH) while improving gastrointestinal tolerability and lowering treatment discontinuations. Imatinib has shown potential to improve pulmonary vascular resistance (PVR) and 6-minute walk distance (6MWD). The adaptive Phase 3 will run in two parts: Part A is a double-blind, placebo-controlled trial of about 140 patients with a primary endpoint of PVR at Week 24; Part B will mirror Part A but enroll about 346 patients with a primary endpoint of 6MWD at Week 24. The design includes a 12-week dose-titration, uninterrupted enrollment between parts, and possible sample-size re-estimation for Part B. The study may be conducted at roughly 180 sites worldwide and could shorten the path to potential approval by about three years.Read Announcement Inhibikase Therapeutics FDA Events - Frequently Asked Questions Has Inhibikase Therapeutics received FDA approval? As of now, Inhibikase Therapeutics (IKT) has not received any FDA approvals for its therapy in the last two years. What drugs has Inhibikase Therapeutics submitted to the FDA? In the past two years, Inhibikase Therapeutics (IKT) has reported FDA regulatory activity for IKT-001. What is the most recent FDA event for Inhibikase Therapeutics? The most recent FDA-related event for Inhibikase Therapeutics occurred on July 23, 2026, involving IKT-001. The update was categorized as "Designation Grant," with the company reporting: "Inhibikase Therapeutics, Inc announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of PAH." What conditions do Inhibikase Therapeutics' current drugs treat? Currently, Inhibikase Therapeutics has one therapy (IKT-001) targeting the following condition: Pulmonary Arterial Hypertension. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events ACADIA Pharmaceuticals FDA EventsEikon Therapeutics FDA EventsIonis Pharmaceuticals FDA EventsKaryopharm Therapeutics FDA EventsPulmonx FDA EventsMetaVia FDA EventsNeonc Technologies FDA EventsRegeneron Pharmaceuticals FDA EventsSELLAS Life Sciences Group FDA EventsSanofi FDA EventsVeru FDA EventsMedtronic FDA EventsAclaris Therapeutics FDA EventsBioVie FDA EventsBioLineRx FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Ardelyx FDA Events Achieve Life Sciences FDA Events Cybin FDA Events Ovid Therapeutics FDA Events Aquestive Therapeutics FDA Events Phathom Pharmaceuticals FDA Events Relmada Therapeutics FDA Events CorMedix FDA Events Assembly Biosciences FDA Events Contineum Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:IKT last updated on 7/23/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Designation Grant - July 23,2026Designation Grant Orphan DrugDrug: IKT-001Announced Date: July 23, 2026Indication: Pulmonary Arterial HypertensionAnnouncementInhibikase Therapeutics, Inc announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of PAH.AI SummaryInhibikase Therapeutics announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to IKT-001, its lead drug candidate for pulmonary arterial hypertension, or PAH. IKT-001 is a prodrug of imatinib mesylate, meaning it is designed to turn into the active medicine in the body. The orphan designation is given to investigational treatments for rare diseases that affect fewer than 200,000 people in the United States. This designation is important because it recognizes PAH as a rare condition and highlights the potential need for new treatment options. For Inhibikase, the FDA decision may also support further development of IKT-001 as it continues testing the drug for this serious disease.Read Announcement
Enrollment Update - April 7,2026Enrollment Update Phase 3Drug: IKT-001Announced Date: April 7, 2026Indication: Pulmonary Arterial HypertensionAnnouncementInhibikase Therapeutics, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 study IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332).AI SummaryInhibikase Therapeutics announced that the first patient has been enrolled in its pivotal Phase 3 study, IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH; NCT07365332). The study tests IKT-001, the Company’s investigational therapy for pulmonary arterial hypertension (PAH), and this enrollment marks the start of the late-stage trial. The IMPROVE-PAH trial will measure pulmonary vascular resistance and other key outcome variables to evaluate whether IKT-001 improves hemodynamics and clinical results for people with PAH. As a pivotal Phase 3 study, its findings will be central to assessing the drug’s safety and effectiveness. The program will continue enrolling patients across trial sites, with subsequent data readouts and analyses planned as the study progresses.Read Announcement
Provided Update - November 20,2025Provided Update Phase 3Drug: IKT-001Announced Date: November 20, 2025Indication: Pulmonary Arterial HypertensionAnnouncementInhibikase Therapeutics, Inc. announced that it expects to advance IKT-001 to a global pivotal Phase 3 clinical study in PAH.AI SummaryInhibikase announced it expects to advance IKT-001, a prodrug of imatinib, into a global pivotal Phase 3 study called IMPROVE-PAH, planned to start in the first quarter of 2026. IKT-001 is designed to deliver imatinib’s anti-proliferative benefits in pulmonary arterial hypertension (PAH) while improving gastrointestinal tolerability and lowering treatment discontinuations. Imatinib has shown potential to improve pulmonary vascular resistance (PVR) and 6-minute walk distance (6MWD). The adaptive Phase 3 will run in two parts: Part A is a double-blind, placebo-controlled trial of about 140 patients with a primary endpoint of PVR at Week 24; Part B will mirror Part A but enroll about 346 patients with a primary endpoint of 6MWD at Week 24. The design includes a 12-week dose-titration, uninterrupted enrollment between parts, and possible sample-size re-estimation for Part B. The study may be conducted at roughly 180 sites worldwide and could shorten the path to potential approval by about three years.Read Announcement